SUPERNUS PHARMACEUTICALS (SUPN) Covered Calls

Supernus Pharmaceuticals Inc specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases.

You can sell covered calls on SUPERNUS PHARMACEUTICALS to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for SUPN (prices last updated Tue 3:50 PM ET):

SUPERNUS PHARMACEUTICALS (SUPN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
47.42 -0.92 47.42 47.43 442K 29 2.5B
Covered Calls For SUPERNUS PHARMACEUTICALS (SUPN)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Nov 16 47 0.35 47.08 -0.2% -2.9%
Dec 21 47 3.80 43.63 7.7% 46.8%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Supernus Pharmaceuticals, Inc. develops and commercializes products for the treatment of central nervous system. It also develops multiple product candidates in psychiatry to address the large market opportunity in the treatment of attention deficit hyperactivity disorder, or ADHD, including ADHD patients with impulsive aggression. The company markets their products in the U.S. through their own focused sales force targeting specialty physicians and seek strategic collaborations with other pharmaceutical companies to license their products outside the U.S. Its neurology portfolio consists of Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended release topiramate). The company's psychiatry product candidates include SPN-810 (molindone hydrochloride), SPN-812 and SPN-809. Supernus Pharmaceuticals was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.